1. Swissmedic. Swissmedic Annual Report 2012. https://www.swissmedic.ch/ueber/00134/00441/00445/00568/index.html?&download=NHzLpZeg7t,lnp6I0NTU042l2Z6ln1ad1IZn4Z2qZpnO2Yuq2Z6gpJCDdYN3fmym162epYbg2c_JjKbNoKSn6A—. Accessed April 2014.
2. Dörr P. Improving agency performance: what needs to be measured? In: McAuslane N, Liberti L, Connelly P, eds. “Regional Alignment in Asia Pacific: What needs to be in the regulatory science “toolkit” to enable good regulatory decision making?” http://www.cirsci.org/system/files/private/January_%202011%20Workshop_070711_lowres.pdf. Published January 2011. Accessed March 2013.
3. Lanier L. Identifying best practice through benchmarking and outcome measurement. Insight. 2004;29:12–14.
4. McAuslane N, Cone M, Collins J, Walker S. Emerging markets and emerging agencies: a comparative study of how key regulatory agencies in Asia, Latin America, the Middle East and Africa are developing regulatory processes and review models for new medicinal products. Therapeutic Innovation & Regulatory Science. 2009;43:349–359.
5. Hirako M, McAuslane N, Salek S, Anderson C, Walker S. A comparison of the drug review process at five international regulatory agencies. Drug Inform J. 2007;41:291–308.